These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 21543226

  • 1. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
    Ramurthy S, Aikawa M, Amiri P, Costales A, Hashash A, Jansen JM, Lin S, Ma S, Renhowe PA, Shafer CM, Subramanian S, Sung L, Verhagen J.
    Bioorg Med Chem Lett; 2011 Jun 01; 21(11):3286-9. PubMed ID: 21543226
    [Abstract] [Full Text] [Related]

  • 2. Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.
    Ramurthy S, Costales A, Jansen JM, Levine B, Renhowe PA, Shafer CM, Subramanian S.
    Bioorg Med Chem Lett; 2012 Feb 15; 22(4):1678-81. PubMed ID: 22264479
    [Abstract] [Full Text] [Related]

  • 3. IRAK-4 inhibitors. Part 1: a series of amides.
    Buckley GM, Gowers L, Higueruelo AP, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V, Fraser JL.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3211-4. PubMed ID: 18474425
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C, Maeda S, Imai K, Yoshida M, Hashimoto Y, Miyachi H.
    Bioorg Med Chem; 2006 Nov 15; 14(22):7625-51. PubMed ID: 16877001
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of novel benzoheterocyclic derivatives as human acrosin inhibitors by scaffold hopping.
    Chen Q, Tian W, Han G, Qi J, Zheng C, Zhou Y, Ding L, Zhao J, Zhu J, Lv J, Sheng C.
    Eur J Med Chem; 2013 Jan 15; 59():176-82. PubMed ID: 23220646
    [Abstract] [Full Text] [Related]

  • 6. Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.
    Ashton KS, St Jean DJ, Poon SF, Lee MR, Allen JG, Zhang S, Lofgren JA, Zhang X, Fotsch C, Hungate R.
    Bioorg Med Chem Lett; 2011 Sep 15; 21(18):5191-6. PubMed ID: 21824779
    [Abstract] [Full Text] [Related]

  • 7. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
    Wilson KJ, Illig CR, Chen J, Wall MJ, Ballentine SK, DesJarlais RL, Chen Y, Schubert C, Donatelli R, Petrounia I, Crysler CS, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Meegalla SK.
    Bioorg Med Chem Lett; 2010 Jul 01; 20(13):3925-9. PubMed ID: 20570147
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S, Subramanian S, Aikawa M, Amiri P, Costales A, Dove J, Fong S, Jansen JM, Levine B, Ma S, McBride CM, Michaelian J, Pick T, Poon DJ, Girish S, Shafer CM, Stuart D, Sung L, Renhowe PA.
    J Med Chem; 2008 Nov 27; 51(22):7049-52. PubMed ID: 18942827
    [Abstract] [Full Text] [Related]

  • 9. Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors.
    Wu Z, Yang C, Graham TH, Verras A, Chabin RM, Xu S, Tong X, Xie D, Lassman ME, Bhatt UR, Garcia-Calvo MM, Shen Z, Chen Q, Bleasby K, Sinharoy R, Hale JJ, Tata JR, Pinto S, Colletti SL, Shen DM.
    Bioorg Med Chem Lett; 2012 Feb 15; 22(4):1727-30. PubMed ID: 22290078
    [Abstract] [Full Text] [Related]

  • 10. Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases.
    Frazier K, Jazan E, McBride CM, Pecchi S, Renhowe PA, Shafer CM, Taylor C, Bussiere D, He MM, Jansen JM, Lapointe G, Ma S, Vora J, Wiesmann M.
    Bioorg Med Chem Lett; 2006 Apr 15; 16(8):2247-51. PubMed ID: 16446087
    [Abstract] [Full Text] [Related]

  • 11. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Chai L, Chaffee SC, Deak HL, Epstein LF, Faust T, Gallant P, Gore A, Gu Y, Henkle B, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, Zhao H, Zhu L, Zhu X.
    J Med Chem; 2008 Mar 27; 51(6):1681-94. PubMed ID: 18321037
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.
    Tully DC, Liu H, Alper PB, Chatterjee AK, Epple R, Roberts MJ, Williams JA, Nguyen KT, Woodmansee DH, Tumanut C, Li J, Spraggon G, Chang J, Tuntland T, Harris JL, Karanewsky DS.
    Bioorg Med Chem Lett; 2006 Apr 01; 16(7):1975-80. PubMed ID: 16446091
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
    Scheiper B, Matter H, Steinhagen H, Böcskei Z, Fleury V, McCort G.
    Bioorg Med Chem Lett; 2011 Sep 15; 21(18):5480-6. PubMed ID: 21840218
    [Abstract] [Full Text] [Related]

  • 16. Novel heterocyclic family of phenyl naphthothiazole carboxamides derived from naphthalimides: synthesis, antitumor evaluation, and DNA photocleavage.
    Li Z, Yang Q, Qian X.
    Bioorg Med Chem; 2005 May 02; 13(9):3149-55. PubMed ID: 15809150
    [Abstract] [Full Text] [Related]

  • 17. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators.
    Pettersson M, Johnson DS, Subramanyam C, Bales KR, am Ende CW, Fish BA, Green ME, Kauffman GW, Lira R, Mullins PB, Navaratnam T, Sakya SM, Stiff CM, Tran TP, Vetelino BC, Xie L, Zhang L, Pustilnik LR, Wood KM, O'Donnell CJ.
    Bioorg Med Chem Lett; 2012 Apr 15; 22(8):2906-11. PubMed ID: 22429469
    [Abstract] [Full Text] [Related]

  • 18. MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.
    Barta TE, Becker DP, Bedell LJ, Easton AM, Hockerman SL, Kiefer J, Munie GE, Mathis KJ, Li MH, Rico JG, Villamil CI, Williams JM.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):2820-2. PubMed ID: 21507637
    [Abstract] [Full Text] [Related]

  • 19. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW, Palmer BD, Bridges AJ, Showalter HD, Sun L, Nelson J, McMichael A, Kraker AJ, Fry DW, Denny WA.
    J Med Chem; 1996 Feb 16; 39(4):918-28. PubMed ID: 8632415
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and biological evaluation of phosphoramide derivatives as urease inhibitors.
    Domínguez MJ, Sanmartín C, Font M, Palop JA, San Francisco S, Urrutia O, Houdusse F, García-Mina J.
    J Agric Food Chem; 2008 May 28; 56(10):3721-31. PubMed ID: 18452297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.